Sept. 24 Webinar: Understand the “Why” Behind Treatment Choices

Walk away with questions to bring to your next appointment — whether you’re newly diagnosed, in treatment, or years into survivorship.

Register

FDA Approves Pluvicto for Metastatic- Hormone Sensitive Prostate Cancer

Learn more about what it could mean for you or a loved one.

Watch Video

PCF Advocates for Veterans on Capitol Hill

PCF President and CEO, Gina Carithers recently testified before the U.S. Senate Committee on Veterans’ Affairs during a hearing focused on the future of VA research.

Watch the Testimony

Gina Carithers U.S. Senate Committee on Veterans' Affairs

PCF Testimony in Support of New Drug Proves a Success

The FDA approved capivasertib with abiraterone and prednisone for metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer patients.

Read More

Gina Carithers headshot with FDA logo- testimony

The Prostate Cancer Foundation has worked since 1993 to end death and suffering from prostate cancer through research, providing effective treatments for patients and families.

About PCF  

Ways to Take Action

Our Work

Patient Support

The Latest

George Zhao, MD

“The Prostate Cancer Foundation Young Investigator Award was crucial in jumpstarting my career. It not only funded important research but also helped me secure a physician-scientist position.”

The Work We Fund

Benny Johnson, Jr.

“Meeting Dr. King made it a little more lighter. When I met her, she told me some things we can do because in between that, my sexual situation was up and down, and more down than up at that particular point. So we figured we had to do something about that.”

Sexual Health